Seres therapeutics to present new post hoc data from ser-155 phase 1b trial at idweek 2025, highlighting potential to improve outcomes in adults undergoing allogeneic hematopoietic stem cell transplant

Cambridge, mass., oct. 14, 2025 (globe newswire) -- seres therapeutics, inc. (nasdaq: mcrb), (seres or the company), a leading live biotherapeutics company, today announced that new post hoc data from its ser-155 phase 1b trial will be featured in an oral presentation at idweek 2025, taking place october 19–22 in atlanta, georgia.
MCRB Ratings Summary
MCRB Quant Ranking